Accueil>>Signaling Pathways>> Neuroscience>> Ophthalmology>>17-phenyl trinor Prostaglandin F2α methyl amide

17-phenyl trinor Prostaglandin F2α methyl amide (Synonyms: Bimatoprost methyl amide, Methylamido Dihydro Noralfaprostal, 17phenyl trinor PGF2α methyl amide)

Catalog No.GC41973

17-phenyl trinor Prostaglandin F2α (17-phenyl trinor PGF2α) is a metabolically stable analog of PGF2α and is a potent agonist for the FP receptor, binding with a relative potency of 756% compared to that of PGF2α.

Products are for research use only. Not for human use. We do not sell to patients.

17-phenyl trinor Prostaglandin F2α methyl amide Chemical Structure

Cas No.: 155206-01-2

Taille Prix Stock Qté
1mg
77,00 $US
En stock
5mg
348,00 $US
En stock
10mg
502,00 $US
En stock
50mg
1 252,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

17-phenyl trinor Prostaglandin F2α (17-phenyl trinor PGF2α) is a metabolically stable analog of PGF2α and is a potent agonist for the FP receptor, binding with a relative potency of 756% compared to that of PGF2α. The ethyl amide of 17-phenyl trinor PGF2α bimatoprost has been approved for use as an ocular hypotensive drug. 17-phenyl trinor PGF2α methyl amide is an analog of bimatoprost. Its biological and toxicological properties have not been evaluated.

Avis

Review for 17-phenyl trinor Prostaglandin F2α methyl amide

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 17-phenyl trinor Prostaglandin F2α methyl amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.